Pitches

3rd FORUM Science & Health
July 5, 2022

Join the Pitch Session

Day 1: July 5, from 12:45 - 13:30, Tenne

Biotype: Bridging the gap. How Biotype can help startups be successful in a competitive market

Biotype: Bridging the gap. How Biotype can help startups be successful in a competitive market

Biotype GmbH is a German biotechnology company with over 20 years of history. Biotype has successfully positioned itself as a trusted provider of state-of-the-art solutions for molecular diagnostics in Europe. Biotype develops, manufactures, and distributes molecular in-vitro diagnostic kits for the detection and quantification of DNA and RNA based biomarkers. The assays support diagnosis and therapy in various molecular applications, such as oncology, infectious diseases, forensics, dermatology and veterinary.

Biotype initially started as a biotechnology company developing molecular diagnostic tests and has grown into a full-service provider offering the complete value chain in molecular in-vitro diagnostics. All our in-house developed tests are multiplex PCR-based and run either on established laboratory platforms or on our proprietary Modaplex device.

The Modaplex system provides a novel real-time quantification procedure through the unique combination of PCR and simultaneous capillary electrophoresis. This technology enables the examination of up to 50 RNA and DNA markers in a single sample. With little hands-on time and a simple workflow, it allows the detection of all types of genetic aberrations.

Biotype’s also offers contract development & manufacturing services that cover all challenges from the idea up to the realization of a marketable product. One of our assets is platform and biomarker flexibility, meaning we design and develop molecular diagnostic assays optimized to customer needs, ranging from a prototype via RUO to CE-IVD. Our development process is modular; CE-IVD development can be paused at the Prototype or the RUO stage, providing our customers with flexibility while developing a molecular diagnostic (MDx) test.

Production at Biotype takes place within well-equipped modern facilities, which include clean rooms, quality-control laboratories, and state-of-the-art equipment. Our facility design allows a unidirectional workflow to minimize in-process contamination risks and follows the rules of good laboratory practice.

The company's goal is to provide customers, such as laboratories, pharmaceutical, and diagnostic companies, with quality and robust molecular diagnostic tools and services.

Zifo Technologies: Digital Transformation

Zifo Technologies: Digital Transformation

Unstructured and unconnected data? What is the sensible path going from paper to digital? How to link information across the value chain? Often the leap from a paper notebooks organization to digital product management organization is too big. Key is to focus on high value areas and a sustainable strategy to become digital. Zifo supports your organization right from Strategic consulting to align with company strategy through to Managed services to ensure smooth running of operations.

Karlsruhe Institute of Technology (KIT): Hybrid Nanoparticles – A Novel Concept for High-Load Drug Cocktails

Karlsruhe Institute of Technology (KIT): Hybrid Nanoparticles – A Novel Concept for High-Load Drug Cocktails

Hybrid Nanoparticles (HyNP) represent a new platform concept for drug delivery with theranostic features. Specifically, a cocktail of two or more drugs can be combined in a single nanoparticle with extremely high drug load (70-90 % of total nanoparticle mass). The HyNP material concept is highly flexible and allows to combine drug cocktails with chemotherapeutic, antibiotic, antiviral or anti-inflammative agents. In vitro and in vivo studies show high efficacy at low side-effects. All HyNP can be enabled with theranostic features (including OI, PAI, MRI, PET). Options for validation and transfer to clinical use are currently evaluated/in preparation.

ProductLife Group

ProductLife Group

ProductLife Group’s mission is to improve human health by delivering regulatory compliance services for the safe and effective use of medical solutions.

Since almost 30 years, PLG supports clients through the entire product life cycle, combining local expertise with global reach spanning more than 150 countries. It provides consulting and outsourcing services in the areas of regulatory affairs, quality and compliance, market access (pricing & reimbursement), vigilances and medical information, covering both established products and innovative therapeutics & diagnostics.

With a goal of continuously improving the value delivered to people and customers, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

V.O. Patents & Trademarks: A new patent system for Europe

V.O. Patents & Trademarks: A new patent system for Europe

Comprehensive IP management and full utilization of your IP strengthens your position over competitors and significantly improves your chances of thriving in a highly competitive market such as bio-tech.

Soon will be the start of the Unitary Patent (UP) and the Unitary Patent Court (UPC) which forms an additional patent system for Europe. The UP is a single patent right which provides unitary patent protection across up to 25 EU Member States. This new system will establish a centralized forum for enforcing and challenging patents in Europe in a very cost-effective way.

We are happy to present the unitary patent system and discuss with you its benefits and potential downsides, especially for small and mid-size biotech companies.


Platinum Sponsor

Silver Sponsors


Get involved

Participate as a sponsor of FORUM Science & Health.
Find out about your sponsoring opportunities
or contact us:
Dr. Andreas Berghammer
berghammer@remove-this.bio-m.org